CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Povidone-Iodine 0.5%Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1669 Machine learning model Wiki 1.00
drug2205 Povidone-Iodine 2% Wiki 1.00
drug1484 Isotonic saline 0.9% Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers

The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."

NCT04347954 COVID-19 Drug: Povidone-Iodine 2% Drug: Povidone-Iodine 0.5% Drug: Isotonic saline 0.9%

Primary Outcomes

Description: Nasopharyngeal swabs will be obtained and quantitative polymerase chain reaction (PCR) testing will be performed to determine the viral load in the nasopharynx

Measure: Mean change in viral titers of SARS-CoV-2

Time: Day 1 (baseline), Day 1 (4 hours), Day 5

Secondary Outcomes

Description: Adverse effects of interest include: Nasal burning/pain Headaches Ear pain Sneezing Nose bleeds

Measure: Frequency of adverse effects of interest after nasal sprays

Time: Up to 5 days

Description: Symptoms of interest include: Fever Fatigue Change in smell Change in taste Nasal obstruction Chills Sore throat

Measure: Frequency of symptoms related to SARS-CoV-2

Time: Up to 5 days

Description: Self report by participants (survey) of estimated doses completed.

Measure: Compliance with study drug administration

Time: Up to 5 days

Description: Participants scratch the cards and attempt to identify the smell from a multiple choice set of options. Their scores are then computed and categorized as normal, mild, moderate, or severe microsmia (loss of smell).

Measure: Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT)

Time: Day 1 (baseline), Day 30

No related HPO nodes (Using clinical trials)